Vía de señalización dependiente de la proteincinasa de activación mitogénica en el carcinoma papilar de tiroides. De las bases moleculares a la práctica clínica

Hundahl, 1998, A National Center Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995, Cancer, 83, 2638, 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1 Ain, 1995, Papillary thyroid carcinoma. Etiology, assessment, and therapy, Endocrinol Metab Clin North Am, 24, 711, 10.1016/S0889-8529(18)30020-3 Mazzaferri, 1994, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer, Am J Med, 97, 418, 10.1016/0002-9343(94)90321-2 Sturgill, 1986, Muscle proteins related to microtubule associated protein-2 are substrates for an insulin-stimulable kinase, Biochem Biophys Res Commun, 134, 565, 10.1016/S0006-291X(86)80457-0 Avruch, 2007, MAP kinase pathways: the first twenty years, Biochim Biophys Acta, 1773, 1150, 10.1016/j.bbamcr.2006.11.006 Fagin, 2004, How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy, J Endocrinol, 183, 249, 10.1677/joe.1.05895 Ciampi, 2007, Minireview: RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis, Endocrinology, 148, 936, 10.1210/en.2006-0921 Soares, 2003, BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC, Oncogene, 22, 4578, 10.1038/sj.onc.1206706 Kimura, 2003, High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma, Cancer Res, 63, 1454 Melillo, 2005, The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells, J Clin Invest, 115, 1068, 10.1172/JCI200522758 Fusco, 1987, A new oncogen in human thyroid paillary carcinomas and their lymph-nodal metastases, Nature, 328, 170, 10.1038/328170a0 Takahashi, 1985, Activation of a novel human transforming gene, ret, by DNA rearrangement, Cell, 42, 581, 10.1016/0092-8674(85)90115-1 Santoro, 2004, Dysfunction of the RET receptor in human cancer, Cell Mol Life Sci, 61, 2954, 10.1007/s00018-004-4276-8 Arighi, 2005, RET tyrosine kinase signaling in development and cancer, Cytokine Growth Factor Rev, 16, 441, 10.1016/j.cytogfr.2005.05.010 Teixeira, 2006, Recurrent fusion oncogenes in carcinomas, Crit Rev Oncog, 12, 257, 10.1615/CritRevOncog.v12.i3-4.40 De Groot, 2006, RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors, Endocr Rev, 27, 535, 10.1210/er.2006-0017 Santoro, 2006, RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology prizze lecture, Eur J Endocrinol, 155, 645, 10.1530/eje.1.02289 Santoro, 1993, The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line, Cell Growth Differ, 4, 77 Jhiang, 1998, Thyroid carcinomas in RET/PTC transgenic mice, Recent Results Cancer Res, 154, 265, 10.1007/978-3-642-46870-4_17 Rhoden, 2006, RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma, J Clin Endocrinol Metab, 91, 2414, 10.1210/jc.2006-0240 Corvi, 2001, Frequent RET rearrangements in thyroid papillary microcarcinoma detected by interphase fluorescence in situ hybridization, Lab Invest, 81, 1639, 10.1038/labinvest.3780377 Fischer, 1998, Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure, Am J Pathol, 153, 1443, 10.1016/S0002-9440(10)65731-8 Cheung, 2001, immunohistochemical diagnosis of papillary thyroid carcinoma, Mod Pathol, 14, 338, 10.1038/modpathol.3880312 Santoro, 2002, RET activation and clinicopathologic features in poorly differentiated thyroid tumors, J Clin Endocrinol Metab, 87, 370, 10.1210/jcem.87.1.8174 Viglietto, 1995, RET/PTC oncogene activation is an early event in thyroid carcinogenesis, Oncogene, 11, 1207 Smida, 1999, Distinc frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus, Int J Cancer, 80, 32, 10.1002/(SICI)1097-0215(19990105)80:1<32::AID-IJC7>3.0.CO;2-L Ito, 1993, In vitro irradiation is able to cause RET oncogene rearrangement, Cancer Res, 53, 2940 Mizuno, 2000, Preferential induction of RET/PTC1 rearrangement by X-ray irradiation, Oncogene, 19, 438, 10.1038/sj.onc.1203343 Hamatani, 2008, RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose, Cancer Res, 68, 7176, 10.1158/0008-5472.CAN-08-0293 Nikiforova, 2000, Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells, Science, 290, 138, 10.1126/science.290.5489.138 Yang, 1997, p53 induced by ionizing radiation mediates DNA endjointing activity, but not apoptosis of thyroid cells, Oncogene, 14, 1511, 10.1038/sj.onc.1200979 Pierotti, 2001, Chromosomal rearrangements in thyroid carcinomas: a recombination or death dilemma, Cancer Lett, 166, 1, 10.1016/S0304-3835(01)00439-6 Puxeddu, 2003, Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas, Eur J Endocrinol, 148, 505, 10.1530/eje.0.1480505 Santoro, 1995, Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation, Eur J Endocrinol, 133, 513, 10.1530/eje.0.1330513 Sugg, 1998, Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia, J Clin Endocrinol Metab, 83, 4116 Tallini, 1998, RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes, Clin Cancer Res, 4, 287 Zafon, 2007, Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma, Histopathology, 50, 225, 10.1111/j.1365-2559.2006.02555.x Zou, 1994, Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from saudi Arabia, Cancer, 73, 176, 10.1002/1097-0142(19940101)73:1<176::AID-CNCR2820730130>3.0.CO;2-T Bongarzone, 1996, Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma, J Clin Endocrinol Metab, 81, 2006 Chiappetta, 2002, The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions, J Clin Endocrinol Metab, 87, 364, 10.1210/jcem.87.1.8180 Fenton, 2000, The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults, J Clin Endocrinol Metab, 85, 1170 Jhiang, 1994, The ret/PTC oncogene in papillary thyroid carcinoma, J Lab Clin Med, 123, 331 Rebelo, 2003, Immunostaining and RT-PCR: different approaches to search for RET rearrangements in patients with papillary thyroid carcinoma, Int J Oncol, 23, 1025 Shin, 2004, Expression of down stream molecules of RET (p-ERK, p-p38 MAPK, p-JNK and p-AKT) in papillary thyroid carcinomas, Yonsei Med J, 45, 306, 10.3349/ymj.2004.45.2.306 Zhu, 2006, Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity, J Clin Endocrinol Metab, 91, 3603, 10.1210/jc.2006-1006 Soares, 1998, Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggresive thyroid neoplasms?, J Pathol, 185, 71, 10.1002/(SICI)1096-9896(199805)185:1<71::AID-PATH42>3.0.CO;2-S Basolo, 2001, RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma, Eur J Endocrinol, 145, 599, 10.1530/eje.0.1450599 Erdogan, 2008, The prevalence of RET/PTC mutations in papillary thyroid cancers in Turkish population and its relation between tumor histopathology and prognostic factors, Exp Clin Endocrinol Diab, 116, 225, 10.1055/s-2007-992153 Musholt, 2000, Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma, Surgery, 128, 984, 10.1067/msy.2000.110845 Mai, 2001, Immunostaining for ret oncogene proteins in papillary thyroid carcinoma: a correlation of ret immunoreactivity and potential of lymph node metastasis, Thyroid, 11, 859, 10.1089/105072501316973118 Miki, 1999, ret/PTC expression may be associated with local invasion of thyroid papillary carcinoma, J Surg Oncol, 71, 76, 10.1002/(SICI)1096-9098(199906)71:2<76::AID-JSO4>3.0.CO;2-0 Alberti, 2003, RET and NTRK1 proto-oncogenes in human diseases, J Cell Physiol, 195, 168, 10.1002/jcp.10252 Pierotti, 2006, Oncogenic rearrangements of the NTRK1/NGF receptor, Cancer Lett, 28, 90, 10.1016/j.canlet.2005.07.043 Greco, 1992, TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas, Oncogene, 7, 237 Brzezianska, 2007, Rearrangements of NTRK1 oncogene in papillary thyroid carcinoma, Neuro Endocrinol Lett, 28, 221 Russell, 2000, The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium, Oncogene, 19, 5729, 10.1038/sj.onc.1203922 Roccato, 2005, Proximity of TPR and NTRK1 rearranging loci in human thyrocytes, Cancer Res, 65, 2572, 10.1158/0008-5472.CAN-04-4294 Bounacer, 2000, Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation, Br J Cancer, 82, 308, 10.1054/bjoc.1999.0920 Rabes, 2000, Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications, Clin Cancer Res, 6, 1093 Brzezianska, 2006, Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population, Mutat Res, 599, 26, 10.1016/j.mrfmmm.2005.12.013 Kuo, 2000, Low frequency of rearrangement of TRK protooncogen in Chinese thyroid tumors, Endocrine, 13, 341, 10.1385/ENDO:13:3:341 Delvincourt, 1996, Ret and trk proto-oncogene activation in thyroid papillary carcinomas in French patients from the Champagne-Ardenne region, Clin Biochem, 29, 267, 10.1016/0009-9120(96)00006-9 Ness, 1996, Cytoplasmic localization of EGF receptor in papillary thyroid carcionomas: association with the 150-kDa receptor form, Int J Cancer, 17, 161, 10.1002/(SICI)1097-0215(19960117)65:2<161::AID-IJC6>3.0.CO;2-X Chen, 1999, Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage, Int J Oncol, 15, 893 Gorgoulis, 1992, Expression of epidermal growth factor, transforming growth factor-alpha and epidermal growth factor receptor in thyroid tumors, In Vivo, 6, 291 Marti, 2001, Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues, Thyroid, 11, 137, 10.1089/105072501300042785 Ensinger, 2004, Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas, Ann NY Acad Sci, 1030, 69, 10.1196/annals.1329.009 Schiff, 2004, Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer, Clin Cancer Res, 10, 8594, 10.1158/1078-0432.CCR-04-0690 Liu, 2008, Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers, J Clin Endocrinol Metab, 93, 3106, 10.1210/jc.2008-0273 Chen, 1999, Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage, Pathol Res Pract, 195, 427, 10.1016/S0344-0338(99)80017-X Zanetti, 1998, Expression of Met protein and urokinase-type plasminogen activator receptor (uPAR-R) in papillary carcinoma of the thyroid, J Pathol, 186, 287, 10.1002/(SICI)1096-9896(199811)186:3<287::AID-PATH175>3.0.CO;2-X Ramirez, 2000, Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma, Clin Endocrinol, 53, 635, 10.1046/j.1365-2265.2000.01124.x Siraj, 2007, Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy, J Pathol, 213, 190, 10.1002/path.2215 Di Renzo, 1995, Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium, J Endocrinol Invest, 18, 134, 10.1007/BF03349722 Nardone, 2003, c-MET expression in tall cell variant papillary carcinoma of the thyroid, Cancer, 98, 1386, 10.1002/cncr.11638 Fluge, 2001, Difference in patterns of Met expression in papillary thyroid carcinomas and nonneoplastic thyroid tissue, World J Surg, 25, 623, 10.1007/s002680020167 Oyama, 1998, c-Met expression of thyroid tissue with special reference to papillary carcinoma, Pathol Int, 48, 763, 10.1111/j.1440-1827.1998.tb03835.x Motti, 2007, Loss of p27 expression through RAS → BRAF → MAP kinase-dependent pathway in human thyroid carcinomas, Cell Cycle, 6, 2817, 10.4161/cc.6.22.4883 Bos, 1989, Ras oncogenes in human cancer: a review, Cancer Res, 49, 4682 Giordano, 2005, Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation specific gene expression profiles discovered by DNA microarray analysis, Oncogene, 24, 6646, 10.1038/sj.onc.1208822 Namba, 1990, H-ras protooncogene mutations in human thyroid neoplasms, J Clin Endocrinol Metab, 71, 223, 10.1210/jcem-71-1-223 Nikiforov, 2008, Thyroid carcinoma: molecular pathways and therapeutic targets, Mod Pathol, 21, S37, 10.1038/modpathol.2008.10 Riesco-Eizaguirre, 2007, New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy, Endocr Relat Cancer, 14, 957, 10.1677/ERC-07-0085 Cyniak-Magierska, 2007, Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS, Exp Clin ndocrinol Diab, 115, 594, 10.1055/s-2007-981670 Lemoine, 1988, Activated ras oncogenes in human thyroid cancers, Cancer Res, 48, 4459 Namba, 1990, Point mutations of ras oncogenes are an early event in thyroid tumorigenesis, Mol Endocrinol, 4, 1474, 10.1210/mend-4-10-1474 Khwaja, 1997, Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway, EMBO, 16, 2783, 10.1093/emboj/16.10.2783 Rak, 1995, Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression, J Cell Biol, 131, 1587, 10.1083/jcb.131.6.1587 Shirokawa, 2000, Conditional apoptosis induced by oncogenic ras in thyroid cells, Mol Endocrinol, 14, 1725, 10.1210/mend.14.11.0559 De Vita, 2005, Dose-dependent inhibition of thyroid differentiation by RAS oncogenes, Mol Endocrinol, 19, 76, 10.1210/me.2004-0172 Di Cristofaro, 2006, Expression of TPO mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, braf, ras and pax8 genes, Endocr Relat Cancer, 13, 485, 10.1677/erc.1.01164 Saavedra, 2000, The RAS oncogene induces genomic inestability in thyroid PCCL3 cells via the MAPK pathway, Oncogene, 19, 3948, 10.1038/sj.onc.1203723 Basolo, 1994, Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer, Eur J Cancer, 30A, 171, 10.1016/0959-8049(94)90081-7 Nikiforov, 2004, Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas, Endocr Pathol, 15, 319, 10.1385/EP:15:4:319 Wang, 2007, Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma, Ann Surg Oncol, 14, 3011, 10.1245/s10434-007-9503-8 Basolo, 2000, N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression, Thyroid, 10, 19, 10.1089/thy.2000.10.19 Garcia-Rostan, 2003, ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer, J Clin Oncol, 21, 3226, 10.1200/JCO.2003.10.130 Mercer, 2003, Raf proteins and cancer: B-Raf is identified as a mutational target, Biochim Biophys Acta, 1653, 25 Robinson, 1997, Mitogen-activated protein pathways, Curr Opin Cell Biol, 17, 5588 Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 Garnett, 2004, Guilty as charged: B-RAF is a human oncogene, Cancer Cell, 6, 313, 10.1016/j.ccr.2004.09.022 Davies, 2002, Mutations in the braf gene in human cancer, Nature, 417, 949, 10.1038/nature00766 Dhillon, 2004, Oncogenic b-raf mutations: crystal clear at last, Cancer Cell, 5, 303, 10.1016/S1535-6108(04)00087-X Pratilas, 2007, Therapeutic strategies for targeting BRAF in human cancer, Rev Recent Clin Trials, 2, 121, 10.2174/157488707780599393 Fukushima, 2003, BRAF mutations in papillary carcinomas of the thyroid, Oncogene, 22, 6455, 10.1038/sj.onc.1206739 Namba, 2003, Clinical implication of hot spot BRAF mutation, V599E in papillary thyroid cancers, J Clin Endocrinol Metab, 88, 4393, 10.1210/jc.2003-030305 Nikiforova, 2003, BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic and poorly differentiated carcinomas arising from papillary carcinomas, J Clin Endocrinol Metab, 88, 5399, 10.1210/jc.2003-030838 Xu, 2003, High prevalence of BRAF gene mutation in papillary thyroid carcinoma and thyroid tumor cell lines, Cancer Res, 63, 4561 Xing, 2005, BRAF mutation in thyroid cancer, Endocr Relat Cancer, 12, 245, 10.1677/erc.1.0978 Ciampi, 2005, Alterations of BRAF gene in thyroid tumors, Endocr Pathol, 16, 163, 10.1385/EP:16:3:163 Unger, 2004, Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas, J Clin Endocrinol Metab, 89, 4272, 10.1210/jc.2003-031870 Bounacer, 1997, High prevalence of activating ret proto- oncogene rearrangements in thyroid tumors from patients who had received external radiation, Oncogene, 15, 1263, 10.1038/sj.onc.1200206 Xing, 2004, BRAF T1796A transversion mutation in various thyroid neoplasms, J Clin Endocrinol Metab, 89, 1365, 10.1210/jc.2003-031488 Ciampi, 2005, Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer, J Clin Invest, 115, 94, 10.1172/JCI23237 Fusco, 2005, A new mechanism of BRAF activation in human thyroid papillary carcinomas, J Clin Invest, 115, 20, 10.1172/JCI200523987 Fugazzola, 2006, Correlation between B-RAF V600E mutation and clinicopathological parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature, Endocr Relat Cancer, 13, 455, 10.1677/erc.1.01086 Puxeddu, 2004, BRAF (V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas, J Clin Endocrinol Metab, 89, 2414, 10.1210/jc.2003-031425 Xing, 2007, BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications, Endocr Rev, 28, 742, 10.1210/er.2007-0007 Cohen, 2004, Mutational analysis of BRAF in the fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules, Clin Cancer Res, 10, 2761, 10.1158/1078-0432.CCR-03-0273 Hayashida, 2004, A rapid and simple detection method for the BRAF (T1796A) mutation in fine-needle aspirated thyroid carcinoma cells, Thyroid, 14, 910, 10.1089/thy.2004.14.910 Salvatore, 2004, Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma, J Clin Endocrinol Metab, 89, 5175, 10.1210/jc.2003-032221 Xing, 2004, Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer, J Clin Endocrinol Metab, 89, 2867, 10.1210/jc.2003-032050 Chang, 2003, Signal transduction mediated by the Ras/ Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention, Leukemia, 17, 1263, 10.1038/sj.leu.2402945 Manash, 2004, Tyrosine kinase-role and significance in cancer, Int J Med Sci, 1, 101 Pinto Couto, 2009, How molecular pathology is changing and will change the therapeutics of patients with follicular cellderived thyroid cancer?, J Clin Pathol Lanzi, 2009, Targeting RET for thyroid cancer therapy, Biochem Pharmacol, 77, 297, 10.1016/j.bcp.2008.10.033 Knowles, 2006, Structure and chemical inhibition of RET tyrosine kinase domain, J Biol Chem, 281, 33577, 10.1074/jbc.M605604200 Sathornsumetee, 2006, Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy, Drugs Today (Barc), 42, 657, 10.1358/dot.2006.42.10.1025318 Carlomagno, 2002, ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases, Cancer Res, 62, 7284 Henderson, 2008, Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement, Clin Cancer Res, 14, 4908, 10.1158/1078-0432.CCR-07-1772 Gupta-Abramson, 2008, Phase II trial of sorafenib in advanced thyroid cancer, J Clin Oncol, 26, 4714, 10.1200/JCO.2008.16.3279 Kim, 2006, An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/Papillary thyroid cancer kinases, J Clin Endocrinol Metab, 91, 4070, 10.1210/jc.2005-2845 Dawson, 2008, Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma, Anticancer Drugs, 19, 547, 10.1097/CAD.0b013e3282fc6cf7 Carlomagno, 2003, Efficient inhibitor of RET/Papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chlorophenyl)- 7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2), J Clin Endocrinol Metab, 88, 1897, 10.1210/jc.2002-021278 Chattopadhyay, 2008, Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma, Head Neck, 30, 991, 10.1002/hed.20816 Mitsutake, 2006, BRAF mediates RET/PTC-induced mitogenactivated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis, Endocrinology, 147, 1014, 10.1210/en.2005-0280 Ouyang, 2006, Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo, Clin Cancer Res, 12, 1785, 10.1158/1078-0432.CCR-05-1729 Chiloeches, 2006, Is BRAF the Achilles’ heel of thyroid cancer?, Clin Cancer Res, 12, 1661, 10.1158/1078-0432.CCR-06-0051 Mitsiades, 2007, Targeting BRAFV600E in thyroid carcinoma: therapeutic implications, Mol Cancer Ther, 6, 1070, 10.1158/1535-7163.MCT-06-0449 Ball, 2007, Selective growth inhibitor in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244, J Clin Endocrinol Metab, 92, 4712, 10.1210/jc.2007-1184 Adjei, 2008, Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers, J Clin Oncol, 26, 2139, 10.1200/JCO.2007.14.4956